Thursday, June 5, 2025 – Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. The power of three: Retatrutide’s role in modern obesity…
Wednesday, June 4, 2025 – Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA…
Wednesday, June 4, 2025 – Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are formulated and administered to achieve optimal therapeutic effect. These drugs…
Wednesday, June 4, 2025 – by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds uncovers the cellular mechanisms behind GLP-1s and other peptides that…
Tuesday, June 3, 2025 – This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor agonists (GLP-1s) for obesity treatment, highlighting their efficacy in weight reduction and other…
Monday, June 2, 2025 – PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo…
Sunday, June 1, 2025 – Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41, no. 3 (Spring 2025): 24–26. Laura A. Schmidt is a…
Saturday, May 31, 2025 – Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific disease or trait. It involves comparing the genomes of individuals with…
Friday, May 30, 2025 – This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of life of patients. The study analyzed data from 80 randomized clinical…
Thursday, May 29, 2025 – May 23, 2025Stat + by Katie Palmer Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the relationship between major pharmaceutical companies like Novo Nordisk and telehealth providers. After…